Stellate Ganglion Block to Treat Long COVID 19 Case Series
CompletedNCT05812209
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
Study details
- Official title
- Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
- Conditions
- Long COVID
- Long Covid19
- Post-COVID-19 Syndrome
- Post Acute COVID-19 Syndrome
- Dysautonomia
- Anosmia
- Dysgeusia
- Brain Fog
- Muscle Pain
- Shortness of Breath
- Dizziness
- Fatigue Post Viral
- Cough
- Menstrual Cycle Abnormal
- Pain
- Interventions
- Procedure: Stellate Ganglion Block
- Sponsor
- Metamorphosis LTD
- Start date
- 2022-09-01
- Primary completion
- 2022-12-31
- Sex
- All
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado. \- Exclusion Criteria: Stellate Ganglion Block Contraindications \-
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05812209